[{"orgOrder":0,"company":"Arena Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Arena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arena Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arena Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Arena Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Etrasimod","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Arena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arena Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Arena Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Abivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"||miR-124","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abivax \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Etrasimod

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.

                          Product Name : ABX464

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 25, 2024

                          Lead Product(s) : Obefazimod,Etrasimod

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Arena Pharmaceuticals

                          Country arrow
                          German Wound Congress
                          Not Confirmed

                          Arena Pharmaceuticals

                          Country arrow
                          German Wound Congress
                          Not Confirmed

                          Details : Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulato...

                          Product Name : APD334

                          Product Type : Other Small Molecule

                          Upfront Cash : $6,700.0 million

                          November 03, 2022

                          Lead Product(s) : Etrasimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Pfizer Inc

                          Deal Size : $6,700.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Arena Pharmaceuticals

                          Country arrow
                          German Wound Congress
                          Not Confirmed

                          Arena Pharmaceuticals

                          Country arrow
                          German Wound Congress
                          Not Confirmed

                          Details : Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena and it's pipeline including lead product etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in development for a range of immuno-inf...

                          Product Name : APD334

                          Product Type : Other Small Molecule

                          Upfront Cash : $6,700.0 million

                          December 13, 2021

                          Lead Product(s) : Etrasimod

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Pfizer Inc

                          Deal Size : $6,700.0 million

                          Deal Type : Acquisition

                          blank